Clinical implementation of a cervical cancer screening program via co-testing at a university hospital

Autores
Denninghoff, Valeria Cecilia; von Petery, Felicitas; Fresno, Cristóbal; Galarza, Mercedes; Torres, Florencia; Avagnina, Alejandra; Fishkel, Vanina; Krupitzki, Hugo Bernardo; Fiorillo, Angel Eduardo; Monge, Fernando Carlos
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The Human Papillomavirus (HPV) test is a crucial technology for cervical cancer prevention because it enables programs to identify women with high-risk HPV infection who are at risk of developing cervical cancer. Current U.S. Preventive Services Task Force recommendations include cervical cancer screening every three years with cervical cytology alone or every five years with either high-risk HPV testing alone or high-risk HPV testing combined with cytology (co-testing). In Argentina, 7, 548 new cervical cancer cases are diagnosed each year with 3, 932 deaths attributed to this cause. Our study aims to show the clinical implementation of a cervical cancer screening program by concurrent HPV testing and cervical cytology (co-testing); and to evaluate the possible cervical cancer screening scenarios for Latin America, focusing on their performance and average cost. A cervical cancer screening five year program via co-testing algorithm (Hybrid-2-Capture/cytology) was performed on women aged 30-65 years old at a university hospital. Statistical analysis included a multinomial logistic regression, and two cancer screening classification alternatives were tested (cytology-reflex and HPV-reflex). A total of 2, 273 women were included, 91.11% of the participants were double-negative, 2.55% double-positive, 5.90% positive-Hybrid-2Capture-/negative-cytology, and 0.44% negative-Hybrid-2-Capture/positive-cytology. A thorough follow-up was performed in the positive-Hybrid-2-Capture group. Despite our efforts, 21 (10.93%) were lost, mainly because of changes on their health insurance coverage which excluded them from our screening algorithm. Of the 171 women with positive-Hybrid-2-Capture results and follow-up, 68 (39.77%) cleared the virus infection, 64 (37.43%) showed viral persistence, and 39 (22.81%) were adequately treated after detection via colposcopy/biopsy of histological HSIL (High-Grade Squamous Intraepithelial Lesion). The prevalence of high-risk HPV in this population was 192 women (8.45%), with HSIL histology detection rates of 17 per 1, 000 screened women. A multinomial logistic regression analysis was performed over the women with positive-Hybrid-2-Capture considering the follow up (clearance, persistence and HSIL) as dependent variable, and the cytology test results (positive- or negative-cytology and Atypical Squamous Cells of Undetermined Significance, ASC-US) as independent variable. The model supported a direct association between cytology test results and follow up: negative-cytology/clearance, ASC-US/persistence, and positive-cytology/HSIL with the following probabilities of occurrence for these pairs 0.5, 0.647 and 0.647, respectively. Cytology could be considered a prognostic-factor in women with a positive-Hybrid-2-Capture. These findings suggest that the introduction of co-testing could diminish the burden of cervical cancer in low-and middle-income-countries, acting as a tool against inequity in healthcare.
Fil: Denninghoff, Valeria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina
Fil: von Petery, Felicitas. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Fresno, Cristóbal. Universidad Anahuac Mexico; México
Fil: Galarza, Mercedes. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Torres, Florencia. No especifíca;
Fil: Avagnina, Alejandra. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Fishkel, Vanina. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Krupitzki, Hugo Bernardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina
Fil: Fiorillo, Angel Eduardo. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Monge, Fernando Carlos. Centro de Educación Medica E Invest.clinicas; Argentina
Materia
CERVICAL CANCER
UNIVERSITY HOSPITAL
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/210314

id CONICETDig_930977f3c91f343e97ea8ec8e852b5df
oai_identifier_str oai:ri.conicet.gov.ar:11336/210314
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Clinical implementation of a cervical cancer screening program via co-testing at a university hospitalDenninghoff, Valeria Ceciliavon Petery, FelicitasFresno, CristóbalGalarza, MercedesTorres, FlorenciaAvagnina, AlejandraFishkel, VaninaKrupitzki, Hugo BernardoFiorillo, Angel EduardoMonge, Fernando CarlosCERVICAL CANCERUNIVERSITY HOSPITALhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3The Human Papillomavirus (HPV) test is a crucial technology for cervical cancer prevention because it enables programs to identify women with high-risk HPV infection who are at risk of developing cervical cancer. Current U.S. Preventive Services Task Force recommendations include cervical cancer screening every three years with cervical cytology alone or every five years with either high-risk HPV testing alone or high-risk HPV testing combined with cytology (co-testing). In Argentina, 7, 548 new cervical cancer cases are diagnosed each year with 3, 932 deaths attributed to this cause. Our study aims to show the clinical implementation of a cervical cancer screening program by concurrent HPV testing and cervical cytology (co-testing); and to evaluate the possible cervical cancer screening scenarios for Latin America, focusing on their performance and average cost. A cervical cancer screening five year program via co-testing algorithm (Hybrid-2-Capture/cytology) was performed on women aged 30-65 years old at a university hospital. Statistical analysis included a multinomial logistic regression, and two cancer screening classification alternatives were tested (cytology-reflex and HPV-reflex). A total of 2, 273 women were included, 91.11% of the participants were double-negative, 2.55% double-positive, 5.90% positive-Hybrid-2Capture-/negative-cytology, and 0.44% negative-Hybrid-2-Capture/positive-cytology. A thorough follow-up was performed in the positive-Hybrid-2-Capture group. Despite our efforts, 21 (10.93%) were lost, mainly because of changes on their health insurance coverage which excluded them from our screening algorithm. Of the 171 women with positive-Hybrid-2-Capture results and follow-up, 68 (39.77%) cleared the virus infection, 64 (37.43%) showed viral persistence, and 39 (22.81%) were adequately treated after detection via colposcopy/biopsy of histological HSIL (High-Grade Squamous Intraepithelial Lesion). The prevalence of high-risk HPV in this population was 192 women (8.45%), with HSIL histology detection rates of 17 per 1, 000 screened women. A multinomial logistic regression analysis was performed over the women with positive-Hybrid-2-Capture considering the follow up (clearance, persistence and HSIL) as dependent variable, and the cytology test results (positive- or negative-cytology and Atypical Squamous Cells of Undetermined Significance, ASC-US) as independent variable. The model supported a direct association between cytology test results and follow up: negative-cytology/clearance, ASC-US/persistence, and positive-cytology/HSIL with the following probabilities of occurrence for these pairs 0.5, 0.647 and 0.647, respectively. Cytology could be considered a prognostic-factor in women with a positive-Hybrid-2-Capture. These findings suggest that the introduction of co-testing could diminish the burden of cervical cancer in low-and middle-income-countries, acting as a tool against inequity in healthcare.Fil: Denninghoff, Valeria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; ArgentinaFil: von Petery, Felicitas. Centro de Educación Medica E Invest.clinicas; ArgentinaFil: Fresno, Cristóbal. Universidad Anahuac Mexico; MéxicoFil: Galarza, Mercedes. Centro de Educación Medica E Invest.clinicas; ArgentinaFil: Torres, Florencia. No especifíca;Fil: Avagnina, Alejandra. Centro de Educación Medica E Invest.clinicas; ArgentinaFil: Fishkel, Vanina. Centro de Educación Medica E Invest.clinicas; ArgentinaFil: Krupitzki, Hugo Bernardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; ArgentinaFil: Fiorillo, Angel Eduardo. Centro de Educación Medica E Invest.clinicas; ArgentinaFil: Monge, Fernando Carlos. Centro de Educación Medica E Invest.clinicas; ArgentinaPublic Library of Science2022-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/210314Denninghoff, Valeria Cecilia; von Petery, Felicitas; Fresno, Cristóbal; Galarza, Mercedes; Torres, Florencia; et al.; Clinical implementation of a cervical cancer screening program via co-testing at a university hospital; Public Library of Science; Plos One; 17; 12-2022; 1-141932-6203CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0278476info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0278476info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:51:39Zoai:ri.conicet.gov.ar:11336/210314instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:51:39.604CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Clinical implementation of a cervical cancer screening program via co-testing at a university hospital
title Clinical implementation of a cervical cancer screening program via co-testing at a university hospital
spellingShingle Clinical implementation of a cervical cancer screening program via co-testing at a university hospital
Denninghoff, Valeria Cecilia
CERVICAL CANCER
UNIVERSITY HOSPITAL
title_short Clinical implementation of a cervical cancer screening program via co-testing at a university hospital
title_full Clinical implementation of a cervical cancer screening program via co-testing at a university hospital
title_fullStr Clinical implementation of a cervical cancer screening program via co-testing at a university hospital
title_full_unstemmed Clinical implementation of a cervical cancer screening program via co-testing at a university hospital
title_sort Clinical implementation of a cervical cancer screening program via co-testing at a university hospital
dc.creator.none.fl_str_mv Denninghoff, Valeria Cecilia
von Petery, Felicitas
Fresno, Cristóbal
Galarza, Mercedes
Torres, Florencia
Avagnina, Alejandra
Fishkel, Vanina
Krupitzki, Hugo Bernardo
Fiorillo, Angel Eduardo
Monge, Fernando Carlos
author Denninghoff, Valeria Cecilia
author_facet Denninghoff, Valeria Cecilia
von Petery, Felicitas
Fresno, Cristóbal
Galarza, Mercedes
Torres, Florencia
Avagnina, Alejandra
Fishkel, Vanina
Krupitzki, Hugo Bernardo
Fiorillo, Angel Eduardo
Monge, Fernando Carlos
author_role author
author2 von Petery, Felicitas
Fresno, Cristóbal
Galarza, Mercedes
Torres, Florencia
Avagnina, Alejandra
Fishkel, Vanina
Krupitzki, Hugo Bernardo
Fiorillo, Angel Eduardo
Monge, Fernando Carlos
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CERVICAL CANCER
UNIVERSITY HOSPITAL
topic CERVICAL CANCER
UNIVERSITY HOSPITAL
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The Human Papillomavirus (HPV) test is a crucial technology for cervical cancer prevention because it enables programs to identify women with high-risk HPV infection who are at risk of developing cervical cancer. Current U.S. Preventive Services Task Force recommendations include cervical cancer screening every three years with cervical cytology alone or every five years with either high-risk HPV testing alone or high-risk HPV testing combined with cytology (co-testing). In Argentina, 7, 548 new cervical cancer cases are diagnosed each year with 3, 932 deaths attributed to this cause. Our study aims to show the clinical implementation of a cervical cancer screening program by concurrent HPV testing and cervical cytology (co-testing); and to evaluate the possible cervical cancer screening scenarios for Latin America, focusing on their performance and average cost. A cervical cancer screening five year program via co-testing algorithm (Hybrid-2-Capture/cytology) was performed on women aged 30-65 years old at a university hospital. Statistical analysis included a multinomial logistic regression, and two cancer screening classification alternatives were tested (cytology-reflex and HPV-reflex). A total of 2, 273 women were included, 91.11% of the participants were double-negative, 2.55% double-positive, 5.90% positive-Hybrid-2Capture-/negative-cytology, and 0.44% negative-Hybrid-2-Capture/positive-cytology. A thorough follow-up was performed in the positive-Hybrid-2-Capture group. Despite our efforts, 21 (10.93%) were lost, mainly because of changes on their health insurance coverage which excluded them from our screening algorithm. Of the 171 women with positive-Hybrid-2-Capture results and follow-up, 68 (39.77%) cleared the virus infection, 64 (37.43%) showed viral persistence, and 39 (22.81%) were adequately treated after detection via colposcopy/biopsy of histological HSIL (High-Grade Squamous Intraepithelial Lesion). The prevalence of high-risk HPV in this population was 192 women (8.45%), with HSIL histology detection rates of 17 per 1, 000 screened women. A multinomial logistic regression analysis was performed over the women with positive-Hybrid-2-Capture considering the follow up (clearance, persistence and HSIL) as dependent variable, and the cytology test results (positive- or negative-cytology and Atypical Squamous Cells of Undetermined Significance, ASC-US) as independent variable. The model supported a direct association between cytology test results and follow up: negative-cytology/clearance, ASC-US/persistence, and positive-cytology/HSIL with the following probabilities of occurrence for these pairs 0.5, 0.647 and 0.647, respectively. Cytology could be considered a prognostic-factor in women with a positive-Hybrid-2-Capture. These findings suggest that the introduction of co-testing could diminish the burden of cervical cancer in low-and middle-income-countries, acting as a tool against inequity in healthcare.
Fil: Denninghoff, Valeria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina
Fil: von Petery, Felicitas. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Fresno, Cristóbal. Universidad Anahuac Mexico; México
Fil: Galarza, Mercedes. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Torres, Florencia. No especifíca;
Fil: Avagnina, Alejandra. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Fishkel, Vanina. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Krupitzki, Hugo Bernardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina
Fil: Fiorillo, Angel Eduardo. Centro de Educación Medica E Invest.clinicas; Argentina
Fil: Monge, Fernando Carlos. Centro de Educación Medica E Invest.clinicas; Argentina
description The Human Papillomavirus (HPV) test is a crucial technology for cervical cancer prevention because it enables programs to identify women with high-risk HPV infection who are at risk of developing cervical cancer. Current U.S. Preventive Services Task Force recommendations include cervical cancer screening every three years with cervical cytology alone or every five years with either high-risk HPV testing alone or high-risk HPV testing combined with cytology (co-testing). In Argentina, 7, 548 new cervical cancer cases are diagnosed each year with 3, 932 deaths attributed to this cause. Our study aims to show the clinical implementation of a cervical cancer screening program by concurrent HPV testing and cervical cytology (co-testing); and to evaluate the possible cervical cancer screening scenarios for Latin America, focusing on their performance and average cost. A cervical cancer screening five year program via co-testing algorithm (Hybrid-2-Capture/cytology) was performed on women aged 30-65 years old at a university hospital. Statistical analysis included a multinomial logistic regression, and two cancer screening classification alternatives were tested (cytology-reflex and HPV-reflex). A total of 2, 273 women were included, 91.11% of the participants were double-negative, 2.55% double-positive, 5.90% positive-Hybrid-2Capture-/negative-cytology, and 0.44% negative-Hybrid-2-Capture/positive-cytology. A thorough follow-up was performed in the positive-Hybrid-2-Capture group. Despite our efforts, 21 (10.93%) were lost, mainly because of changes on their health insurance coverage which excluded them from our screening algorithm. Of the 171 women with positive-Hybrid-2-Capture results and follow-up, 68 (39.77%) cleared the virus infection, 64 (37.43%) showed viral persistence, and 39 (22.81%) were adequately treated after detection via colposcopy/biopsy of histological HSIL (High-Grade Squamous Intraepithelial Lesion). The prevalence of high-risk HPV in this population was 192 women (8.45%), with HSIL histology detection rates of 17 per 1, 000 screened women. A multinomial logistic regression analysis was performed over the women with positive-Hybrid-2-Capture considering the follow up (clearance, persistence and HSIL) as dependent variable, and the cytology test results (positive- or negative-cytology and Atypical Squamous Cells of Undetermined Significance, ASC-US) as independent variable. The model supported a direct association between cytology test results and follow up: negative-cytology/clearance, ASC-US/persistence, and positive-cytology/HSIL with the following probabilities of occurrence for these pairs 0.5, 0.647 and 0.647, respectively. Cytology could be considered a prognostic-factor in women with a positive-Hybrid-2-Capture. These findings suggest that the introduction of co-testing could diminish the burden of cervical cancer in low-and middle-income-countries, acting as a tool against inequity in healthcare.
publishDate 2022
dc.date.none.fl_str_mv 2022-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/210314
Denninghoff, Valeria Cecilia; von Petery, Felicitas; Fresno, Cristóbal; Galarza, Mercedes; Torres, Florencia; et al.; Clinical implementation of a cervical cancer screening program via co-testing at a university hospital; Public Library of Science; Plos One; 17; 12-2022; 1-14
1932-6203
CONICET Digital
CONICET
url http://hdl.handle.net/11336/210314
identifier_str_mv Denninghoff, Valeria Cecilia; von Petery, Felicitas; Fresno, Cristóbal; Galarza, Mercedes; Torres, Florencia; et al.; Clinical implementation of a cervical cancer screening program via co-testing at a university hospital; Public Library of Science; Plos One; 17; 12-2022; 1-14
1932-6203
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0278476
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0278476
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083043336388608
score 13.22299